Cosmetic Claim vs Drug Claim

Under the United States Federal Food, Drug, and Cosmetic Act, a cosmetic is an article applied to the body for cleansing, beautifying, promoting attractiveness, or altering the appearance. A drug is an article intended for the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Intent is established from labelling, advertising, brand websites, and sponsored social media, not from what the bottle contains. The same serum can be either, depending on what its maker says about it.

The consequence is the evidence burden. Cosmetics need no premarket approval; the Modernization of Cosmetics Regulation Act of 2022 added facility registration, product listing, safety substantiation, and adverse event reporting, but no approval step. Drugs require an approved application or a monograph. Assignment also varies by jurisdiction: sunscreens are over-the-counter drugs in the United States and cosmetics in the European Union. The FDA has issued warning letters to skincare firms whose sites claimed products stimulate collagen synthesis, treating those as unapproved new drug claims. Cosmeceutical is a marketing coinage with no legal status.

This is why label language is so carefully hedged. Reduces the appearance of fine lines is a cosmetic claim needing no efficacy dossier; rebuilds dermal collagen is a structure-function assertion that puts the product in drug territory.

Two mirror-image errors follow. One is reading appearance-only wording as an admission that the product is inert, when it is a regulatory choice rather than a scientific one. The other is treating a bold mechanistic claim in an influencer video or founder interview as though it carried the standing of an approved label. Advertising substantiation is separately enforced by the Federal Trade Commission, which reaches claims wherever they are made.